Yale study gives insights on hypertrophic cardiomyopathy management
Until recently, patients with the rare and potentially deadly cardiac condition were advised to avoid vigorous exercise. A new, Yale-led study finds otherwise. (Source: Yale Science and Health News)
Source: Yale Science and Health News - March 13, 2023 Category: Universities & Medical Training Source Type: news
Telehealth use for behavioral health increases 45X since pandemic onset and more digital health briefs
Viz.ai also announced an agreement with Bristol Myers Squibb to identify patients with hypertrophic cardiomyopathy. (Source: mobihealthnews)
Source: mobihealthnews - March 10, 2023 Category: Information Technology Source Type: news
Time to Ease Exercise Restrictions in Patients With HCM? Time to Ease Exercise Restrictions in Patients With HCM?
Electrophysiologists John Mandrola, MD. and Rachel Lampert, MD, review the LIVE-HCM study comparing vigorous and nonvigorous exercise in people with hypertrophic cardiomyopathy.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 10, 2023 Category: Consumer Health News Tags: Cardiology Expert Interview Source Type: news
Even Vigorous Exercise Appears Safe for HCM Patients: LIVE-HCM Even Vigorous Exercise Appears Safe for HCM Patients: LIVE-HCM
Patients with hypertrophic cardiomyopathy should no longer be routinely saddled with restriction from intense exercise or sports, which don ' t add to their arrhythmic risk, a large study suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 8, 2023 Category: Consumer Health News Tags: Cardiology News Source Type: news
Cytokinetics heart failure drug turned back by FDA
The company is turning its attention to another drug, which is in a late-stage clinical trial in a genetic heart disease, obstructive hypertrophic cardiomyopathy, that in 1993 killed Boston Celtics star Reggie Lewis. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 1, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Sudden Cardiac Death in HCM Often Preceded by Symptoms
WEDNESDAY, Sept. 28, 2022 -- A majority of cases of sudden cardiac death (SCD) with hypertrophic cardiomyopathy (HCM) present with possible cardiac symptoms before death, and a considerable proportion have a known cardiac disorder prior to death,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 28, 2022 Category: Pharmaceuticals Source Type: news
Study: Many Sudden Cardiac Deaths in Young People Avoidable Study: Many Sudden Cardiac Deaths in Young People Avoidable
Better screening could predict and prevent as many as 90% of sudden cardiac deaths in young people with hypertrophic cardiomyopathy, a new study found.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 15, 2022 Category: Cardiology Tags: Family Medicine/Primary Care News Source Type: news
Aggressive Alcohol Septal Ablation for HCM Holds Up, Pacemakers Notwithstanding
(MedPage Today) -- The occurrence of high-grade conduction disturbances after alcohol septal ablation (ASA) did not translate into worse long-term survival for people with obstructive hypertrophic cardiomyopathy (HCM), a registry study showed... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 14, 2022 Category: Cardiology Source Type: news
Uncovering new approaches to a common inherited heart disorder
New Yale research provides a mechanism to identify abnormalities linked with hypertrophic cardiomyopathy, the most common hereditary cardiac condition. (Source: Yale Science and Health News)
Source: Yale Science and Health News - July 29, 2022 Category: Universities & Medical Training Source Type: news
May 13 2022 This Week in Cardiology May 13 2022 This Week in Cardiology
Obstructive hypertrophic cardiomyopathy and mavacamten, SGLT2 inhibitors, the triple whammy, espresso, and clinician burnout are the topics John Mandrola, MD, covers in today ’s podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 13, 2022 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
FDA Approves Camzyos (mavacamten) for the Treatment of Symptomatic NYHA Class II-III Obstructive Hypertrophic Cardiomyopathy
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of adults with symptomatic New... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 30, 2022 Category: Drugs & Pharmacology Source Type: news
FDA OKs heart drug at center of $13 billion deal for Peninsula company
A heart drug at the center of Bristol-Myers Squibb Co.'s $13 billion acquisition of a Peninsula company 18 months ago was approved Thursday by federal regulators.
Mavacamten, which will be branded as Camzyos and sold for $89,500 a year after the Food and Drug Administration's approval, is designed to treat adults with symptomatic obstructive hypertrophic cardiomyopathy, or HCM, a genetic heart condition.
HCM makes the heart wall thicken so the heart pumps blood less efficiently. The condition,… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 29, 2022 Category: Health Management Authors: Ron Leuty Source Type: news
Cardiac Myosin Inhibitor Gets FDA's Blessing for Obstructive HCM
(MedPage Today) -- The FDA approved mavacamten (Camzyos) for the treatment of obstructive hypertrophic cardiomyopathy (HCM) in people with New York Heart Association class II-III symptoms -- but on the condition it would only be available through... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 29, 2022 Category: Cardiology Source Type: news
ACC: Mavacamten Cuts Need for Surgery in Hypertrophic Cardiomyopathy
MONDAY, April 11, 2022 -- For patients with obstructive hypertrophic cardiomyopathy (HCM), mavacamten improves symptoms and reduces the need for septal reduction therapy (SRT), according to a study presented at the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 11, 2022 Category: Pharmaceuticals Source Type: news
Mavacamten Controlled Hypertrophic Cardiomyopathy for > 1 Year Mavacamten Controlled Hypertrophic Cardiomyopathy for > 1 Year
Open-label mavacamten for a median of 62 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy showed ongoing safety and efficacy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 4, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
